Riskpilot← Back to searchSign inGet full accessSwetrade Pharmaceuticals AB
ABActiveOrg 5566646385Sydhamnsvägen 57Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20040 employees
Revenue 2024
SEK 3,2M
+19% vs 2023
EBITDA margin
7.5%
+79% vs 2023
Equity ratio
50.8%
Financial strength
Net profit 2024
SEK 242K
+77% vs 2023
| Revenue | SEK 3,2M | +19% |
| EBITDA | SEK 241K | +79% |
| Net profit | SEK 242K | +77% |
| Total assets | SEK 2,4M | +24% |
| Equity | SEK 1,2M | +24% |
| Employees | 0 | — |
Legal name
Swetrade Pharmaceuticals AB
Org number
5566646385
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10 augusti 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva partihandel med läkemedel, samt därmed förenlig verksamhet.
Address
Sydhamnsvägen 57
Phone
+46703775566
Email
ulf.hofman@swetradepharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 1 753 | 2 490 | 2 281 | 1 836 | 2 440 | 2 688 | 3 194 |
| Staff expenses | — | — | — | — | — | — | — | −248 | −309 | −389 |
| EBITDA | −152 | −133 | −16 | 73 | 320 | 231 | 147 | 41 | 134 | 241 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — |
| EBIT | −152 | −133 | −16 | 73 | 320 | 231 | 147 | 41 | 134 | 241 |
| Net financials | −671 | 39 | 18 | 20 | −236 | −242 | — | 48 | 2 | 1 |
| Profit before tax | −823 | −94 | 1 | 93 | 202 | 109 | 147 | 90 | 137 | 242 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — |
| Net profit | −823 | −94 | 1 | 93 | 202 | 109 | 147 | 90 | 137 | 242 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 656 | 1 595 | 1 146 | 1 405 | 1 658 | 2 058 | 1 756 | 2 110 | 1 950 | 2 424 |
| Equity | 54 | 211 | 212 | 304 | 506 | 615 | 762 | 852 | 988 | 1 230 |
| Long-term debt | 1 360 | 1 110 | 610 | 610 | 610 | 610 | 603 | 591 | 591 | 588 |
| Short-term debt | 242 | 274 | 325 | 491 | 542 | 833 | 392 | 668 | 371 | 606 |
| Total debt | 1 602 | 1 384 | 935 | 1 101 | 1 152 | 1 443 | 995 | 1 258 | 962 | 1 194 |
EBITDA margin
7.5%
This company
15.8%
Market median
-53% vs market
20152024
Equity ratio
50.8%
This company
38.2%
Market median
+33% vs market
20152024
Return on equity
19.7%
This company
18.4%
Market median
+7% vs market
20152024
Net profit margin
7.6%
This company
8.1%
Market median
-6% vs market
20152024
Asset turnover
1.32×
This company
1.12×
Market median
+18% vs market
20152024
Debt / equity
0.97×
This company
0.62×
Market median
+56% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HC Chief Auditor | Chief Auditor | 2022 | — | — |
LE Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Swetrade Holding AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Swetrade Holding AB
Swetrade Pharmaceuticals AB Board members of Swetrade Pharmaceuticals AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Håkan Claes Anders Karlén | Chief Auditor | 0 companies |
| Lars-Erik Engberg | Audit | 0 companies |
| Ulla Birgitta Hofman | Deputy Board Member | 0 companies |
| Ulf Gerhard Hofman | Board of Directors | 0 companies |